

## Disclosures

- No conflict of interest
- **Funding Sources:**
  - ✓ French Society of Cardiology
  - ✓ ADETEC: Association Chirurgicale pour le Développement et l'Amélioration des Techniques de Dépistage et de Traitement des Maladies Cardiovasculaires

Non-Steroidal Anti-Inflammatory (NSAIDs)  
Treatment for Post-Operative Pericardial  
Effusion: The POPE Study  
**A Multicenter, Double-Blind,**

Ph Meurin, JY Tabet, G Thabut, P  
Cristofini,

T Farrokhi, M Fischbach, B Pierre, A Ben  
Driss,

N Renaud, MC Iliou, H Weber.

Les Grands Prés, Villeneuve Saint Denis; Hôpital Broussais, Paris; Hôpital Bichat,  
Paris; Hôpital Bligny, Briss sous Forges; I.R. S Marcy l'étoile, Château Lemoine, Cenon.

France



on behalf of the French Society of  
Cardiology

## Post Operative Pericardial Effusions

- Frequent:
  - ✓ 50–80% of cardiac operated patients
- Asymptomatic; spontaneously decrease within 2–4 weeks
- Can convert into cardiac tamponade (CT):
  - 1 % of operated patients:
    - 1/3: early CTs: day 1– day 7: due to intra- pericardial bleeding
    - 2/3: late CTs: day 8 – day 30:  
mechanism:  
inflammation and bleeding

## NSAIDs as a Treatment of Post

- Prescribed in 40–77% of the patients<sup>1</sup> having an effusion

### Although:

- Is it effective ?:
  - ✓ no study has ever shown their efficacy for this condition
- Is it dangerous ?:
  - ✓ multiplies by 1.5 to 2 the risk of myocardial infarction and acute heart failure
  - ✓ by 3 renal failure (x 6 if ACE-I co-administration)
  - ✓ by 4 gastrointestinal tract bleeding (x 8 if co-administration of a VKA or low dose aspirin)

(1) Tsai W, Garcia JE, Hayes SN, et al. Mayo Clinic Experience 1979–1998. Chest 1999;116:322-

## POPE Study


- **Objective**: to assess whether the NSAID diclofenac was effective in reducing post operative pericardial effusion volume.
- **Design**: multicenter, randomized, double-blind, placebo-controlled study
- **Setting**: five post operative cardiac rehabilitation centers (POCRC).
- **Patients**: 196 patients at high risk of tamponade

# Quantification and Spontaneous Evolution of Post Operative Pericardial Effusions

## Echocardiographic classification<sup>1</sup>

Grade at day 15	Loculated	Circumferential	Estimated Late CT risk at day 30 <sup>1</sup>
0	0	0	0%
1 Small	< 10 mm	0	0%
2 Moderate	10-14 mm	< 10 mm	7%
3 Medium	15-19 mm	10 -14 mm	15%
4 large	≥ 20 mm	≥ 15 mm	43%

## Spontaneous evolution<sup>1</sup>



## POPE Study: Methods (1)

- Inclusion criteria:
  - ✓ Persistent pericardial effusion  $\geq$  grade 2 on the echocardiography performed at admission in POCRC (8 to 30 days after surgery)


## Methods (2): Primary Efficacy (Echographic) Endpoint and Statistical Power

- Mean pericardial effusion grade (MPEG) decrease
  - ✓ Between the inclusion and the final echocardiographies
  - ✓ Expected to be of 0.6 grade in the placebo group
- Sample size assessment: 86 patients by group
  - ✓ 80% power to detect a supplementary reduction of 50% of the MPEG with diclofenac (versus placebo)
  - ✓ two-sided type 1 error of 5 %

# Results





# From January 2006 to January 2009



## Baseline Characteristics


	Placebo Group (n = 98)	Diclofenac Group (n = 98)
Mean Age (SD ), years	62.5 (12)	64.1 (11)
Male (%)	78%	82%
Surgery performed		
- CABG	57%	60%
- Ao Valve Replacement	32%	35%
- Mitral Valve Replacement	20%	11%
Delay surgery-	15.9 (5.1)	15.9 (4.3)
Oral anticoagulants	43%	44%
- INR at inclusion	2.77 (1.12)	2.51 (0.91)
Aspirin	75%	72%
<b>POPE mean grade:</b>	<b>2.58 (0.73)</b>	<b>2.75 (0.81)</b>
grade 2, n	55	47
grade 3, n	29	28
grade 4, n	14	23

# Primary Endpoint: Mean Pericardial Effusion Grade Decrease



Grade	Placebo	Diclofenac	Mean (95% CI)	p
Initial	2.58 (0.73)	2.75 (0.81)		
Final	1.49 (1.22)	1.39 (1.20)		
Change	-1.08 (1.20)	-1.36 (1.25)	0.28 (-0.63 to 0.06)	0.11

## Secondary Endpoints



Late Tamponades

- placebo group → n = 11 (11.2%)
- ▲ diclofenac group → n = 9 (9.2%)

	Placebo Group	Diclofenac Group	p
Patients with at least 1 grade	<b>73 (74.4%)</b>	<b>71 (72.4%)</b>	0.7
Mean reduction of the pericardial echo free space	<b>-4.8 (7.0)</b>	<b>-6.7 (7.4)</b>	0.07

## Prespecified Sub-Groups Analysis

MPEG decrease (grades) in	Placebo Group (n=98)	Diclofenac	95% CI	p
With CRP level $\geq$ 30mg/l	-1.35 (1.26)	-1.64 (1.16)	0.29 (-0.8 to 0.23)	0.26
Receiving an oral anticoagulant (n=85)	-1.17 (1.37)	-1.56 (1.26)	0.38(-0.96 to 0.18)	0.18
Per Protocol Analysis (n=185)	-1.11 (SD 1.21)	-1.35 (SD 1.27)	0.25 (-0.60 to 0.11)	0.25

## Remarks

- High power of the study to assess NSAID effectiveness
  - ✓ Theoretical sample size: 172
    - included: 196
- Study underpowered to test NSAID tolerance

## Conclusion

- Patients with a persistent moderate to large pericardial effusion more than 7 days after cardiac surgery are at high risk:
  - ✓ 10% pericardial drainages in the 2 following weeks
- NSAID administration seems to be useless in this setting

## Thanks to:

- **POPE study investigators**

- ✓ Les Grands Prés (CRCB): P Meurin, H Weber, JY Tabet, A Ben Driss, N Renaud, A Grosdemouge.
- ✓ Broussais Hospital: P Cristofini, MC Iliou.
- ✓ Bligny Hospital: T Farrokhi, S Corone.
- ✓ Château Lemoine: M Fischbach.
- ✓ IRIS: B Pierre, JL Genoud, F Boucher

- ADETEC: Association Chirurgicale pour le Développement et l'Amélioration des Techniques de Dépistage et de Traitement des Maladies Cardiovasculaires

- Dr A Bouzamondo (French Society of Cardiology)

- The Patients